Velinotamig, a BCMAxCD3 T Cell Engager, Achieves Complete Renal Responses and Significantly Reduces Disease Activity in Systemic Lupus Erythematosus in Data Presented at ACR Convergence 2026
Globe Newswire•08/11/2026•10:30 ET
3
Key Highlights
- ➤8 of 9 evaluable patients achieved clinically meaningful SLEDAI-2K reductions
- ➤5 of 7 patients had rapid, marked proteinuria reductions
- ➤4 patients achieved complete renal responses within 24 weeks
- ➤12 patients treated across three multi-dose cohorts as of September 8
- ➤No dose-limiting toxicities, ICANS, or Grade 3+ CRS observed
Expert Statements
Jeffrey Jones, Chief Medical Officer of Cullinan Therapeutics
“These compelling early findings demonstrate consistent and meaningful clinical, serological, and pharmacodynamic evidence in most treated patients, further validating the therapeutic potential of velinotamig as a short-duration BCMA-directed therapy.”
Jeffrey Jones, Chief Medical Officer of Cullinan Therapeutics
“Combined with the favorable safety profile observed to date, these data reinforce our confidence in the global development plan for velinotamig, including our initial focus on autoimmune cytopenias, where pathogenic autoantibody-producing plasma cells play a central role in disease pathogenesis.”
Jeffrey Jones, Chief Medical Officer of Cullinan Therapeutics
“Our unique and complementary clinical stage BCMA- and CD19-directed T cell engager portfolio positions us to address the diverse biology of autoimmune diseases, with the goal of bringing differentiated and tailored treatment options to more patients across a broad range of conditions.”
Clinically meaningful improvement in disease activity among 8 of 9 evaluable patients, including rapid and marked reductions in proteinuria with complete renal responses
Deep and sustained reduction in pathogenic autoantibodies and IgG reduction underscore potential in plasma-cell driven diseases
Get started
Create a free account to read the full story.